<--GAT-->

Metformin Shows Promise for Increasing NSCLC Survival

by U.S. Medicine

November 9, 2017

BETHESDA, MD—Past research has raised the possibility that a common blood sugar-lowering drug could be associated with improved survival in cancer patients with Type 2 diabetes.

A study published recently in the International Journal of Cancer assessed whether metformin use is associated with overall survival among Type 2 diabetic patients diagnosed with non-small cell lung cancer (NSCLC) in the MHS.1

Data from the linked database of the DoD’s Central Cancer Registry (CCR) and the MHS Data Repository (MDR) were employed for the study led by researchers from the John P. Murtha Cancer Center at Walter Reed National Military Medical Center in Bethesda.

Included were 636 patients with diabetes who also had histologically confirmed NSCLC diagnosed between 2002 and 2007. During the median follow-up time of 14.6 months, 411 of the patients died.

Results indicated that increased postdiagnosis cumulative use (per one year of use) of metformin conferred a significant reduction in mortality, for an adjusted hazard ratio (HR) of 0.76. Upon further analysis by duration of use, researchers determined that, compared to nonusers, the lowest risk reduction occurred among patients with the longest duration of use—i.e., use for more than two years—for an HR of 0.19.

In addition, the study authors pointed out, reduced mortality was particularly observed only among patients who also used metformin before lung cancer diagnosis and among patients at early Stage of diagnosis.

“Prolonged duration of metformin use in the study population was associated with improved survival, especially among early Stage patients,” the study team concluded. “Future research with a larger number of patients is warranted.”

1 Lin J, Gill A, Zahm SH, Carter CA, Shriver CD, et. al. Metformin use and survival after non-small cell lung cancer: A cohort study in the US Military health system. Int J Cancer. 2017 Jul 15;141(2):254-263. doi: 10.1002/ijc.30724. Epub 2017 May 4. PubMed PMID: 28380674.


Comments are closed here.


Related Articles

Racial Disparities Found in BRCA Testing, Counseling

DURHAM, NC—Despite increases in BRCA mutation testing, racial/ethnic disparities in counseling and testing have persisted for decades, a study argued. The review published in the Journal of Racial and Ethnic Health Disparities said its purpose... View Article

VA Guideline Addresses Dental Management of Head/Neck Cancer Patients

SAN FRANCISCO—Few protocols have been published for the dental management of patients with head and neck cancer to prevent complications from head and neck radiation therapy, according to a new study.  The report in the... View Article


U.S. Medicine Recommends


More From oncology

Oncology

Racial Disparities Found in BRCA Testing, Counseling

DURHAM, NC—Despite increases in BRCA mutation testing, racial/ethnic disparities in counseling and testing have persisted for decades, a study argued. The review published in the Journal of Racial and Ethnic Health Disparities said its purpose... View Article

Oncology

VA Guideline Addresses Dental Management of Head/Neck Cancer Patients

SAN FRANCISCO—Few protocols have been published for the dental management of patients with head and neck cancer to prevent complications from head and neck radiation therapy, according to a new study.  The report in the... View Article

Oncology

Patients Treated with Thiopurines Have Higher Skin Cancer Mortality

PHILADELPHIA—Treatment with thiopurines is associated with an increased risk of squamous cell carcinoma of the skin in patients with inflammatory bowel diseases. An article in Clinical Gastroenterology and Hepatology discussed results of a study that... View Article

Oncology

Overcoming Radiation Resistant Prostate Cancer

LOS ANGELES—For nearly half of the patients with localized advanced prostate cancer, radiation therapy is the primary intervention and standard of care for recurrent disease following surgery. The problem is that nearly 30% to 50%... View Article

Oncology

JAK Enzymes Can Treat Leukemia, Lymphoma

NASHVILLE, TN—Precision oncology prescribes the use of molecularly-targeted therapy directed by identification of genomic alterations. A new study suggested the approach is particularly applicable to neoplasms that are resistant to standard cytotoxic chemotherapy, such as... View Article

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up